US Reversal Frames Issues In Myriad's Appeal

Law360, New York (November 12, 2010, 11:03 AM EST) -- The past few weeks have seen important developments in Myriad Genetics Inc.’s appeal to the U.S. Court of Appeals for the Federal Circuit in Association for Molecular Pathology, et al., v. U.S. Patent and Trademark Office, et al., No. 2010-1406, a case with significant implications for the biotechnology industry.

Myriad’s appeal challenges the ruling of the U.S. District Court for the Southern District of New York that patent claims directed to isolated DNA molecules and diagnostic methods using those isolated molecules are invalid because they do...
To view the full article, register now.